QUIREDEX: Revlimid (Lenalidomide) and Dexamethasone (ReDex) Treatment Versus Observation in Patients With Smoldering Multiple Myeloma With High Risk of Progression

This study has been completed.
Sponsor:
Collaborator:
Celgene Corporation
Information provided by:
PETHEMA Foundation
ClinicalTrials.gov Identifier:
NCT00480363
First received: May 28, 2007
Last updated: July 30, 2013
Last verified: July 2013